Brief: Alphamab Oncology Says U.S. FDA Granted Orphan Drug Designation To KN046
03/09/2020 16:01
Sept 3 (Reuters) - Alphamab Oncology 9966.HK :
* FDA GRANTED ORPHAN DRUG DESIGNATION TO KN046, A
RECOMBINANT
HUMANIZED PD-L1/CTLA-4 BISPECIFIC ANTIBODY
* U.S. FDA GRANTED ORPHAN DRUG DESIGNATION TO KN046
Source text for Eikon: urn:newsml:reuters.com:*:nHKS8ZykH7
Further company coverage: 9966.HK
(Reuters.Briefs@thomsonreuters.com)
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)